Providence Therapeutics Holdings Inc.

2 clinical trials · Sponsor

Record	Firm	Date
PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine. (NCT05175742)	Providence Therapeutics Holdings Inc.	2021-08-17
PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64 (NCT04765436)	Providence Therapeutics Holdings Inc.	2021-01-14

Every clearance here is in the API, with alerts when new ones post.